EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

Is November 27, 2026 still the small-dispenser DSCSA deadline?

Dose Diligence research deskSection 04 · Page 10 of 17Last updated 17 Nov 2026

Not for the specified requirements covered by FDA’s new exemption. FDA’s August 6, 2026 letter extends those exemptions from November 27, 2026 through November 27, 2027. Eligibility uses the corporate owner’s total of 25 or fewer full-time licensed pharmacists or qualified pharmacy technicians as of November 27, 2026—not the clinic’s prescriber count or the staffing of one selected branch. Other DSCSA requirements remain applicable. FDA exemption letter. (fda.gov)

FDA says qualifying entities need not submit anything to FDA to use the exemption. Nevertheless, our recommendation is to retain an eligibility calculation, identify the provisions relied upon and tell trading partners how transactions will be handled. FDA exemption page. (fda.gov)

Clinic applicability needs its own analysis. The statute contains exceptions from specified tracing and verification requirements for certain licensed practitioners acting in ordinary professional practice. That is not an exemption from every DSCSA obligation. FDA’s April 1, 2026 Pure Indulgence Aesthetics warning letter, involving botulinum-toxin sourcing rather than GLP-1s, illustrates enforcement of authorised-trading-partner requirements against a medical spa. Statutory text; warning letter. (fda.gov)

Buyer action: map obligations by legal entity, product and transaction. Do not buy traceability software solely because the organisation has 60 prescribers, and do not accept a blanket “physician exemption” from a seller.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/media/194424/download
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/title-ii-drug-quality-and-security-act
  4. fda.gov · Source 4 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-indulgence-aesthetics-723267-04012026
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/title-ii-drug-quality-and-security-act?utm_source=openai
Section sources →